This increased risk is highest when you first start taking birth control pills and when you restart the same or different birth control pills after not using them for a month or more.

This includes starting the pack late. Consider a visit with your healthcare provider for a pre-pregnancy checkup before you stop taking the pill.Your healthcare provider prescribed Yasmin for you.

Unable to load your delegates due to an error

Some women may encounter post-pill amenorrhea or oligomenorrhea, especially when such a condition was pre-existent.If withdrawal bleeding does not occur, consider the possibility of pregnancy. When switching from an intrauterine contraceptive or an implant, Yasmin should be started on the day of removal.1. The US pivotal clinical study (N=326) was a multicenter, open-label trial in healthy women aged 18 -35 who were treated for up to 13 cycles. The results of all of these studies are presented in Figure 1.Figure 11: VTE Risk with Yasmin Relative to LNG-Containing COCs (adjusted riskRisk ratios displayed on logarithmic scale; risk ratio < 1 indicates a lower risk of VTE for DRSP, > 1 indicates an increased risk of VTE for DRSP. If the bleeding occurs in more than one cycle, is unusually heavy, or lasts for more than a few days, call your healthcare provider.Some women may not have a menstrual period but this should not be cause for alarm as long has you have taken the pills regularly on time.It is not uncommon to miss your period. When switching from an intrauterine contraceptive or an implant, Yasmin should be started on the day of removal.Withdrawal bleeding usually occurs within 3 days following the last yellow tablet. If you have diarrhea or if you take certain medicines, including some antibiotics and some herbal products such as St. John's Wort, your pills may not work as well.Use a back-up method (such as condoms and spermicides) until you check with your healthcare provider.6.

Excretion of DRSP was nearly complete after ten days and amounts excreted were slightly higher in feces compared to urine.

BMJ 5. She should take one yellow Yasmin daily for 21 consecutive days, followed by one white tablet daily on Days 22 through 28.

Rupture of hepatic adenomas may cause death through intra-abdominal hemorrhage.Studies have shown an increased risk of developing hepatocellular carcinoma in long-term (>8 years) COC users. After passage through the cell membrane corticosteroids react with receptor proteins in the cytoplasm to form a steroid-receptor complex. This results in a maximal daily dose of about 0.003 mg DRSP in an infant.Safety and efficacy of Yasmin has been established in women of reproductive age. Other possible mechanisms may include cervical mucus changes that inhibit sperm penetration and endometrial changes that reduce the likelihood of implantation.Drospirenone is a spironolactone analogue with anti-mineralocorticoid activity. If you are currently on daily, long-term treatment for a chronic condition with any of the medications below, you should consult your healthcare provider about whether Yasmin is right for you, and during the first month that you take Yasmin, you should have a blood test to check your potassium level.Your chance of getting pregnant depends on how well you follow the directions for taking your birth control pills. (drospirenone and ethinyl estradiol tablets) 3 mg/0.03 mgThis product (like all oral contraceptives) is intended to prevent pregnancy. COCs should not be used during pregnancy to treat threatened or habitual abortion.Women who do not breastfeed may start COCs no earlier than four weeks postpartum.When possible, advise the nursing mother to use other forms of contraception until she has weaned her child.

Known risk factors for VTE include smoking, obesity, and family history of VTE, in addition to other factors that contraindicate use of COCs A number of studies have compared the risk of VTE for users of Yasmin to the risk for users of other COCs, including COCs containing levonorgestrel. Estrogen-containing COCs can reduce milk production in breastfeeding mothers.

The second pivotal study (N=442)was a multicenter, randomized, open-label comparative European study of Yasmin vs. 0.150 mg desogestrel/0.03 mg EE conducted in healthy women aged 17-40 who were treated for up to 26 cycles.The most common adverse reactions (≥ 2% of users) were: premenstrual syndrome (13.2%), headache/migraine (10.7%), breast pain/tenderness/discomfort (8.3%), nausea/vomiting (4.5%) abdominal pain/discomfort/tenderness (2.3%) and mood changes (depression, depressed mood, irritability, mood swings, mood altered and affect lability (2.3%).Of 2,837 women, 6.7% discontinued from the clinical trials due to an adverse reaction; the most frequent adverse reaction leading to discontinuation was headache/migraine (1.5%).Depression, pulmonary embolism, toxic skin eruption, and uterine leiomyoma.The following adverse reactions have been identified during post-approval use of Yasmin.